The Afonin Lab pioneered the development of functional nucleic acid nanoparticles (NANPs) as versatile platforms for a broad spectrum of biomedical applications, including cancer, infectious diseases, cardiovascular disorders, and biosensing. The research has advanced the understanding of NANPs' biocompatibility, stability, and synergy with conventional treatments, propelling the creation of safer, more precise, and modular solutions for next-generation personalized diagnostics.